Erythrocyte fatty acids as potential biomarkers in the diagnosis of advanced lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer.

OBJECTIVES To analyze the fatty acid profiles of erythrocyte total lipids from patients with advanced squamous cell lung carcinoma (SCC), lung adenocarcinoma (ADC), and small cell lung cancer (SCLC) and benign lung diseases (chronic obstructive pulmonary disease [COPD] and asthma) to reveal the fatty acids that could be used as lung cancer biomarkers. METHODS Thirty, 20, 15, 17, and 19 patients with SCC, ADC, SCLC, COPD, and asthma, respectively, and 55 healthy participants were enrolled in our study. Fatty acid profiles were investigated using gas chromatography/mass spectrometry followed by receiver operating characteristic (ROC) curve analysis. Sialic acid (SA) and cytokeratins were measured by the thiobarbituric acid and immunoradiometric methods, respectively. RESULTS At least one of the main fatty acids might be used as a biomarker for every type of lung cancer: arachidonic (20:4n6), linoleic (18:2n6), and stearic (18:0) acids for ADC, SCC, and SCLC, respectively. These fatty acids showed diagnostic yields and operating characteristics similar to or higher than the commonly used SA or cytokeratin markers. CONCLUSIONS Fatty acids from erythrocyte total lipids might be used as diagnostic biomarkers of lung ADC, SCC, and SCLC. Their use in different aspects of the disease process needs to be explored.

[1]  A. Marcus,et al.  Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. , 1991, The Journal of clinical investigation.

[2]  K. Kaplan,et al.  Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. , 1981, Blood.

[3]  Joachim Thiery,et al.  LC-MS-based metabolomics in the clinical laboratory. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  Sriram Krishnamoorthy,et al.  Lipoxygenase metabolism: roles in tumor progression and survival , 2007, Cancer and Metastasis Reviews.

[5]  J. Pujol,et al.  Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. , 1996, American journal of respiratory and critical care medicine.

[6]  D. Alberts,et al.  Fatty Acid Composition of Red Blood Cell Membranes and Risk of Squamous Cell Carcinoma of the Skin , 2005, Cancer Epidemiology Biomarkers & Prevention.

[7]  M. Páez de la Cadena,et al.  Clinical Significance of Preoperative Serum Sialic Acid Levels in Colorectal Cancer: Utility in the Detection of Patients at High Risk of Tumor Recurrence , 2004, The International journal of biological markers.

[8]  D AMINOFF,et al.  Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. , 1961, The Biochemical journal.

[9]  L. Tamer,et al.  The Levels of Serum Vitamin C, Malonyldialdehyde and Erythrocyte Reduced Glutathione in Chronic Obstructive Pulmonary Disease and in Healthy Smokers , 2002, Clinical chemistry and laboratory medicine.

[10]  E. Tabakoğlu,et al.  High plasma D-dimer level is associated with decreased survival in patients with lung cancer. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[11]  M. J. Burgueño,et al.  Las curvas ROC en la evaluación de las pruebas diagnósticas , 1995 .

[12]  D. Ferrigno,et al.  Cytokeratin-derived markersof lung cancer , 2001 .

[13]  J. Dufour,et al.  Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. , 2011, Cancer research.

[14]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[15]  Michael J. González,et al.  Erythrocyte membrane fatty acid composition in cancer patients. , 2004, Puerto Rico health sciences journal.

[16]  R. Deberardinis,et al.  Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? , 2012, Cell.

[17]  Vicenta S Martínez-Zorzano,et al.  Erythrocyte and Platelet Phospholipid Fatty Acids as Markers of Advanced Non-Small Cell Lung Cancer: Comparison with Serum Levels of Sialic Acid, TPS and Cyfra 21-1 , 2008, Cancer investigation.

[18]  J. De Castro,et al.  Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma , 2007, Platelets.

[19]  F. Berrino,et al.  Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. , 2001, Journal of the National Cancer Institute.

[20]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[21]  Y. Nakanishi,et al.  Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. , 2013, Lung cancer.

[22]  C. Tan,et al.  Exploratory investigation of plasma metabolomics in human lung adenocarcinoma. , 2013, Molecular bioSystems.

[23]  R. Abbate,et al.  Increased thromboxane A2 generation and altered membrane fatty acid composition in platelets from patients with active angina pectoris. , 1986, Thrombosis research.

[24]  U. Das,et al.  Essential fatty acids: biochemistry, physiology and pathology , 2006, Biotechnology journal.

[25]  W. Malorni,et al.  Radical generation and alterations of erythrocyte integrity as bioindicators of diagnostic or prognostic value in COPD? , 2008, Antioxidants & redox signaling.

[26]  J. Sánchez-Yagüe,et al.  Increase in vulnerability to oxidative damage in cholesterol-modified erythrocytes exposed to t-BuOOH. , 2005, Biochimica et biophysica acta.

[27]  J. Groopman,et al.  Chemotherapy-induced anemia in adults: incidence and treatment. , 1999, Journal of the National Cancer Institute.

[28]  J. De Castro,et al.  Comparison of Changes in Erythrocyte and Platelet Fatty Acid Composition and Protein Oxidation in Advanced Non-Small Cell Lung Cancer , 2006, Cancer investigation.

[29]  L. Warren,et al.  The thiobarbituric acid assay of sialic acids. , 1959, The Journal of biological chemistry.

[30]  Y. She,et al.  Identification of Metal-binding Proteins in Human Hepatoma Lines by Immobilized Metal Affinity Chromatography and Mass Spectrometry* , 2003, Molecular & Cellular Proteomics.

[31]  R. Abbate,et al.  Platelet activation and platelet lipid composition in pulmonary cancer. , 1995, Prostaglandins, leukotrienes, and essential fatty acids.

[32]  R. Rawal,et al.  Comparison between serum levels of carcinoembryonic antigen, sialic acid and phosphohexose isomerase in lung cancer. , 1995, Neoplasma.

[33]  V. Shnyrov,et al.  Alterations in erythrocyte membrane protein composition in advanced non-small cell lung cancer. , 2006, Blood cells, molecules & diseases.

[34]  R. Abbate,et al.  Altered membrane fatty acid composition and increased thromboxane A2 generation in platelets from patients with diabetes. , 1989, Prostaglandins, leukotrienes, and essential fatty acids.

[35]  A. Brunati,et al.  Human red blood cells alterations in primary aldosteronism. , 2013, The Journal of clinical endocrinology and metabolism.

[36]  J. De Castro,et al.  Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer. , 2009, Experimental and molecular pathology.

[37]  C. Kevil,et al.  The red blood cell and vascular function in health and disease. , 2004, Antioxidants and Redox Signaling.

[38]  M. Metintaş,et al.  Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. , 2001, Lung cancer.

[39]  David M Erceg-Hurn,et al.  Modern robust statistical methods: an easy way to maximize the accuracy and power of your research. , 2008, The American psychologist.

[40]  A. Blázovics,et al.  Oxidative stress with altered element content and decreased ATP level of erythrocytes in hepatocellular carcinoma and colorectal liver metastases , 2008, European journal of gastroenterology & hepatology.

[41]  J. Stanford,et al.  The association of fatty acids with prostate cancer risk , 2001, The Prostate.

[42]  W. Malorni,et al.  Structural changes of the erythrocyte as a marker of non-insulin-dependent diabetes: protective effects of N-acetylcysteine. , 2002, Biochemical and biophysical research communications.

[43]  Gonzalo López-Abente,et al.  Lung cancer mortality in towns near paper, pulp and board industries in Spain: a point source pollution study , 2008, BMC public health.

[44]  Q. Zhan,et al.  Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers* , 2013, Molecular & Cellular Proteomics.

[45]  J. Goo,et al.  Receiver Operating Characteristic (ROC) Curve: Practical Review for Radiologists , 2004, Korean journal of radiology.

[46]  M. Burgueno,et al.  [ROC curves in the evaluation of diagnostic tests]. , 1995, Medicina clinica.

[47]  L. Parise,et al.  Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. , 2001, The Journal of clinical investigation.

[48]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[49]  J. Kouvaris,et al.  Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy. , 1992, Anticancer research.

[50]  T. Perneger.  What's wrong with Bonferroni adjustments , 1998, BMJ.

[51]  S. Narayanan,et al.  Sialic acid as a tumor marker. , 1994, Annals of clinical and laboratory science.

[52]  A. Gornall,et al.  Determination of serum proteins by means of the biuret reaction. , 1949, The Journal of biological chemistry.

[53]  Arachidonic acid and cancer risk: a systematic review of observational studies , 2012, BMC Cancer.